A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.

Diabetes, obesity & metabolism

Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.

Diabetes, obesity & metabolism

Comment on 'The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies'.

Diabetes, obesity & metabolism

Copper peptide activated cascade catalysis for glucose regulation and hypoxia reversing in infected diabetic wound healing.

Materials today. Bio

Comparative Positioning of Orforglipron Among Selected GLP-1 Receptor Agonist Benchmarks: A Narrative Review.

Cureus

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.

Headache

GLP-1 receptor agonists in pediatric obesity.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

GLP-1 Receptor Agonist Therapy in Children and Adolescents with Obesity: A Network Meta-Analysis of Differential Cardiometabolic Efficacy and Safety Profiles.

Pharmacological research

Hims & Hers is going all-in on #peptides. Is $HIMS evolving from a GLP-1 to a peptide company? Let's discuss in the comments 👇 ❤️ Like 🟦 Save 🔁 Repost $HIMS is actively building operational capacity for peptide active pharmaceutical ingredient (API) production. The company https://t.co/YU99GqkJR5

BREAKING $HIMS Another Upgrade| $40| BUY rating🚀 This only proves @MikeLongTerm was right again and again and again! These PTs are still very behind with FY2026 Revenue and earning growth or FY2027. Analysts will soon be revised nonstop to 3 digits IMO. Not Financial Advice! https://t.co/P53V80HOpX https://t.co/6xXvbCMgBK

Three things reshaping the peptide industry right now: • Medicare now covers GLP-1s for weight loss $50/mo, first time ever (launched July 1) • FDA panel decides July 23 on BPC-157, TB-500, Semax + 4 more • Novartis bet up to $1.7B on peptide drugs Federal access.

https://t.co/XHq5rZw8Em The article reports that the FDA has significantly changed the makeup of the upcoming advisory panel that will review several peptide drugs, including BPC-157 and TB-500, ahead of the July meeting. New panel composition: Previous FDA advisory panels were

Top compounds on PeptideBase by provider coverage: 1. Semaglutide — 676 2. Tirzepatide — 444 3. BPC-157 — 402 4. NAD+ — 349 5. Sermorelin — 333 6. Ipamorelin — 320 7. CJC-1295 — 306 Coverage = where the market concentrated, not where the evidence is. Disclaimer: Research use

Key Points ⚡ Peptides are short chains of amino acids that primarily function as highly specific biological signaling molecules. ⚡ Peptides can be thought of as the body’s “biological software,” delivering instructions that regulate repair, metabolism, inflammation, collagen https://t.co/KHVDqDGYr9

@IhabFathiSulima The most likely reason is: > History of Medullary Thyroid Carcinoma (MTC) or MEN2 syndrome. ⚠️ Why? Ozempic (semaglutide), a GLP-1 receptor agonist, carries a boxed warning and is contraindicated in patients with: 🦋 Personal or family history of Medullary Thyroid Carcinoma

RT @MounjaroNotes: Tirzepatide is GLP-1 + GIP, but semaglutide is more GLP-1-heavy. Since GLP-1 plays a major role in satiety and hunger s…